Sarah Lightdale

Practice Areas

Sarah Lightdale represents clients in high-stakes securities and M&A litigation.

Sarah guides public and private companies, individual directors and officers, investment banks, and private equity and venture capital firms through:

- Securities class actions

- M&A-related disputes, including fiduciary duty claims, stockholder class actions, appraisal proceedings, and busted deal cases

- Internal investigations

- Inquiries by the US Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA)

- Books-and-records inspection demands

- Trade secret disputes

- Contract disputes

She also counsels boards and special committees on transaction processes, fiduciary duties, disclosure obligations, shareholder activism, and regulatory risks.

A trusted advisor to senior management, Sarah brings deep familiarity with Delaware Chancery practice to her clients’ most consequential disputes, including those arising from transformational transactions, disclosure events, and periods of market volatility.

Before rejoining Latham, Sarah was a partner at another global law firm, where she led teams on complex securities and M&A disputes, advised boards on governance, disclosure, and investigations, and held firm leadership roles. She began her career at Latham’s New York office, where she spent over ten years as associate and counsel. She clerked for Judge Eric N. Vitaliano of the US District Court for the Eastern District of New York.

Clients

Sarah’s notable matters include representation of:

* NVIDIA and certain of its officers in a securities class action in the US District Court for the Northern District of California

* Oak View Group and one of its executives in securing a summary judgment victory in the Delaware Court of Chancery against claims for breach of fiduciary duty and conspiracy by a former employee of a sports technology-focused startup; Sarah argued the motion for summary judgment, and the plaintiff declined to appeal

* EHang Holdings and its executives in securing victory in a securities class action in the US District Court for the Southern District of New York alleging EHang investors lost tremendous value following the publication of a scathing short seller report involving the company’s revenues and sales contracts; after Sarah presented oral argument, the court granted our motion to dismiss, the lead plaintiff subsequently declined to amend the complaint, and the court entered final judgment in favor of EHang

* GENFIT and several current and former directors and officers in securing a victory in a securities class action in New York Supreme Court alleging the company made false or misleading statements in its initial public offering documents about the clinical trials of its lead drug product candidate; the court granted our motion to dismiss with prejudice, and the ruling was affirmed on appeal by the Appellate Division’s First Department – Sarah argued both the motion to dismiss and the appeal

* Meredith in securing victory in a consolidated securities class action in the US District Court for the District of Iowa alleging the company made false and misleading statements regarding the expected profitability of its acquisition of Time; the court granted our motion to dismiss, and the dismissal was affirmed on appeal by the US Court of Appeals for the Eighth Circuit – Sarah argued both the motion to dismiss and the appeal

* MindMed in pursuing and achieving a favorable resolution of litigation in the Southern District of New York alleging defendants’ violations of the federal securities laws governing proxy solicitations, as well as litigation against a former executive in the US District Court for the District of Nevada for breaching nondisparagement and confidentiality obligations

* CenturyLink and certain current and former directors and officers in successfully resolving a long-running securities class action and shareholder derivative suits in a multidistrict litigation in the US District Court for the District of Minnesota, as well as related litigation in Louisiana state court, alleging the company misled investors by failing to disclose an alleged cramming scheme

* Malibu Boats in a securities class action in the Southern District of New York alleging the company was at risk of litigation from one of its leading dealers

* Outlook Therapeutics in a securities class action in the US District Court for the District of New Jersey following the Food and Drug Administration’s issuance of a complete response letter denying the company’s Biologics License Application for the company’s lead product candidate

* Verrica Pharmaceuticals and several of its current and former executives in a securities class action in the US District Court for the Eastern District of Pennsylvania alleging the company misled investors about the prospects for regulatory approval of one of its lead product candidates

* Former directors and officers of Altor BioScience in successfully resolving long-running litigation in the Delaware Court of Chancery involving breach of fiduciary duty and appraisal claims related to the company’s sale to NantCell

* BioIQ in litigation related to its acquisition by LetsGetChecked; following expedited litigation by BioIQ in the Delaware Court of Chancery, the parties agreed to a voluntary dismissal with prejudice, and the merger was consummated

* Former directors and officers of Mindbody in successfully resolving litigation in the Delaware Court of Chancery involving breach of fiduciary duty and federal securities fraud claims arising from Vista Equity Partners’ $1.9 billion buyout of Mindbody

* Cantor Fitzgerald and its chairman and CEO in a class action in the Delaware Court of Chancery involving breach of fiduciary duty claims related to the reorganization of BGC Partners from an Up-C to a traditional full C corporation

* The founder and CEO of a biotech company in an arbitration brought by a former employer alleging misappropriation of trade secrets, breach of fiduciary duty and other claims

* Numerous public companies and boards of directors in successfully resolving stockholder demands and litigation related to the adequacy of merger-related disclosures, as well as regulatory inquiries, enabling transactions to close on time

* Numerous special purpose acquisition companies (SPACs) and companies that have gone public through mergers with SPACs in connection with shareholder demands and litigation related to the adequacy of transaction-related disclosures, as well as regulatory inquiries

* A premier boutique investment bank in advising on numerous sets of shareholder disclosure demands and FINRA information requests related to high-profile deals where it served as financial adviser, as well as an SEC investigation of potential insider trading related to a prior deal where the client was involved

* An online consumer marketplace and software solutions provider in internal and SEC investigations and related threatened shareholder litigation and inspection demands pertaining to its reporting of key business metrics

* NewLink Genetics and former directors and officers in successfully resolving a securities class action in the Southern District of New York and the US Court of Appeals for the Second Circuit in relation to the announcement of phase III trial results

* Art.com in defending against shareholder claims in Alameda County Superior Court

* Former directors of Sequenom in securing a victory in a securities class action suit in the US District Court for the Southern District of California brought by investors alleging the board misled them by approving LabCorp’s $371 million takeover of the company; the court granted our motion to dismiss

* Ooyala Holdings in defending against appraisal claims in the Delaware Court of Chancery

* Good Technology and former directors and officers in successfully resolving shareholder litigation in the Delaware Court of Chancery involving breach of fiduciary duty and appraisal claims arising from the sale of the company to BlackBerry

* Former directors and officers of Occam Networks in successfully resolving shareholder litigation in the Delaware Court of Chancery alleging breach of fiduciary duty claims arising from Calix’s acquisition of Occam